Amy E. Juedes

Array ( [id] => 12217560 [patent_doc_number] => 20180055919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'ANTIGEN SPECIFIC TREGS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS' [patent_app_type] => utility [patent_app_number] => 15/499805 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 23334 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15499805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956046 [patent_doc_number] => 11059888 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Regulatory T cell activator and use thereof [patent_app_type] => utility [patent_app_number] => 16/095024 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 63 [patent_no_of_words] => 15644 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001864 [patent_doc_number] => 20170306020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/489189 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 129 [patent_figures_cnt] => 129 [patent_no_of_words] => 80631 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001867 [patent_doc_number] => 20170306022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/489209 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 130 [patent_figures_cnt] => 130 [patent_no_of_words] => 81688 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001866 [patent_doc_number] => 20170306021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/489192 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 128 [patent_figures_cnt] => 128 [patent_no_of_words] => 81643 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16985500 [patent_doc_number] => 11072656 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-27 [patent_title] => Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof [patent_app_type] => utility [patent_app_number] => 15/489666 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 31420 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18246830 [patent_doc_number] => 11603403 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Anti-human vista antibodies and use thereof [patent_app_type] => utility [patent_app_number] => 15/489245 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 128 [patent_figures_cnt] => 155 [patent_no_of_words] => 75928 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001868 [patent_doc_number] => 20170306024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/489254 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 129 [patent_figures_cnt] => 129 [patent_no_of_words] => 81532 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001865 [patent_doc_number] => 20170306019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/489164 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 130 [patent_figures_cnt] => 130 [patent_no_of_words] => 81712 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17586545 [patent_doc_number] => 11324787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Analytical methods and arrays for use in the same [patent_app_type] => utility [patent_app_number] => 16/084788 [patent_app_country] => US [patent_app_date] => 2017-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 13 [patent_no_of_words] => 25419 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 325 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11820633 [patent_doc_number] => 20170209570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'Carbon Nanotube Compositions and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/462320 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 28314 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11954747 [patent_doc_number] => 20170258898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'VERSIKINE FOR INDUCING AND POTENTIATING AN IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 15/454496 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 23784 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15454496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11937737 [patent_doc_number] => 20170241887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Isolating Cells Expressing Secreted Proteins' [patent_app_type] => utility [patent_app_number] => 15/443290 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23910 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15443290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12227545 [patent_doc_number] => 09914780 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-13 [patent_title] => 'Depletion of plasmacytoid dendritic cells' [patent_app_type] => utility [patent_app_number] => 15/442157 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 23 [patent_no_of_words] => 15318 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15442157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13970489 [patent_doc_number] => 10214587 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => Depletion of plasmacytoid dendritic cells [patent_app_type] => utility [patent_app_number] => 15/442147 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 23 [patent_no_of_words] => 14199 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15442147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17014132 [patent_doc_number] => 11083751 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Tumor-associated dendritic cell preparations and uses thereof [patent_app_type] => utility [patent_app_number] => 16/079674 [patent_app_country] => US [patent_app_date] => 2017-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 13 [patent_no_of_words] => 13724 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016563 [patent_doc_number] => 20190070275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => NEOANTIGEN COMPOSITIONS AND METHODS OF USING THE SAME IN IMMUNOONCOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/086556 [patent_app_country] => US [patent_app_date] => 2017-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834698 [patent_doc_number] => 20170216417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'POPULATION OF IMMUNOREGULATORY T CELLS SPECIFIC FOR AN IRRELEVANT ANTIGEN AND USES THEREOF FOR PREVENTING OR TREATING IMMUNE DISEASES' [patent_app_type] => utility [patent_app_number] => 15/426881 [patent_app_country] => US [patent_app_date] => 2017-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11119 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15426881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834636 [patent_doc_number] => 20170216355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'Methods and Compositions for Enhancing T Cell Function and Survival' [patent_app_type] => utility [patent_app_number] => 15/422706 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 11841 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743978 [patent_doc_number] => 20170198050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'MULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/404016 [patent_app_country] => US [patent_app_date] => 2017-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 25939 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15404016 [rel_patent_id] =>[rel_patent_doc_number] =>)